A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy

Date

08 Oct 2016

Session

Poster Display

Presenters

Enrico Mini

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

E. Mini1, R. D'Aurizio2, G. Perrone3, A. Magi3, A. Lapucci3, R. Tassi3, C. Napoli4, L. Picariello5, I. Landini3, M. Brugia3, T. Mazzei4, F. Tonelli5, S. Nobili4

Author affiliations

  • 1 Experimental And Clinical Medicine, University of Florence, 50139 - Firenze/IT
  • 2 Lism-iit, National Research Council, Pisa/IT
  • 3 Experimental And Clinical Medicine, University of Florence, Firenze/IT
  • 4 Health Sciences, University of Florence, Firenze/IT
  • 5 Biomedical Experimental And Clinical Sciences “mario Serio”, University of Florence, Firenze/IT
More

Resources

Background

5-year overall survival of stage III colorectal cancer (CRC) patients (pts) treated with standard adjuvant (adjuv) chemotherapy (CHT) (a fluoropyrimidine, FP +/- oxaliplatin, OHP) is still unsatisfactory and highly variable (42-88%). Although in CRC single molecular biomarkers or molecular signatures predictive of adjuv CHT outcome have been identified, none of them has been validated. The goal of this study was to identify and validate molecular biomarkers predictive of response to FP-based adjuv CHT in stage III CRC pts.

Methods

From a large case series of CRC pts who received adjuv CHT (a FP +/- OHP) we selected two groups with favorable (F) (no evidence of disease recurrence (DR) within 5 yrs from CHT, n = 12) or unfavorable (UNF) (evidence of DR within 3 yrs from CHT, n = 12) prognosis. We used fresh frozen CRC explants according to an IRB approved protocol. Global gene expression profile was performed by Ion Proton System. Differentially expressed genes between groups were identified and some of them, selected according to a preliminary candidature on the basis of literature data or their pathobiological role, were validated by RT-PCR.

Results

Bioinformatic analysis identified 108 differentially expressed genes between groups (p value

Conclusions

Stage III CRC pts with F and UF prognosis following adjuv CHT differs at a transcriptomic level. These findings may have important implications for FP-based adjuv CHT.

Clinical trial identification

-

Legal entity responsible for the study

University of Florence

Funding

Istituto Toscano Tumori (Florence) - Ente Cassa di Risparmio di Firenze (Florence)

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings